The estimated Net Worth of Ivor Royston is at least $326 Tisíc dollars as of 8 March 2016. Ivor Royston owns over 150,000 units of Biocept Inc stock worth over $326,412 and over the last 11 years he sold BIOC stock worth over $0. In addition, he makes $0 as Independent Director at Biocept Inc.
Ivor has made over 3 trades of the Biocept Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 150,000 units of BIOC stock worth $1,800,000 on 8 March 2016.
The largest trade he's ever made was buying 150,000 units of Biocept Inc stock on 8 March 2016 worth over $1,800,000. On average, Ivor trades about 9,863 units every 23 days since 2014. As of 8 March 2016 he still owns at least 750,545 units of Biocept Inc stock.
You can see the complete history of Ivor Royston stock trades at the bottom of the page.
Dr. Ivor Royston M.D. serves as Independent Director of the Company. Dr. Royston currently serves as CEO of Viracta Therapeutics, Inc. From 1990 to 2000, he served as founding President and CEO of The Sidney Kimmel Cancer Center and from 1978 to 1990, he was a member of the oncology faculty of the University of California, San Diego. In addition to being a co-founder of Hybritech, Inc., in 1986 he co-founded IDEC Corporation, which later merged with Biogen to form Biogen Idec. From 1990 to 2017, Dr. Royston was the Founding Managing Partner of Forward Ventures and has been instrumental in the formation, financing and development of numerous biotechnology companies, including Applied Molecular Evolution (acquired by Eli Lilly), Corixa (acquired by GlaxoSmithKline), Dynavax, LigoCyte (acquired by Takeda), Morphotek (acquired by Eisai), Sequana Therapeutics (acquired by Celera), Syndax, TargeGen (acquired by Sanofi-Aventis), and Triangle Pharmaceuticals (acquired by Gilead). He is currently a director of Viracta. Dr. Royston received his B.A. and M.D. degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. In 1997, President Clinton appointed Dr. Royston to a six-year term on the National Cancer Advisory Board. We selected Dr. Royston to serve on our board of directors due to his extensive experience with emerging life sciences companies. Dr. Royston also serves as chair of our science, technology and clinical affairs committee and as a member of our nominating and governance committee.
Ivor Royston is 75, he's been the Independent Director of Biocept Inc since 2010. There are 1 older and 17 younger executives at Biocept Inc. The oldest executive at Biocept Inc is Margaret Faye Wilson, 82, who is the Lead Independent Director.
Ivor's mailing address filed with the SEC is C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Biocept Inc have traded over $2,456 worth of Biocept Inc stock and bought 1,703,300 units worth $1,869,312 . The most active insiders traders include Claire Reiss, Edward A. Neff a David F Hale. On average, Biocept Inc executives and independent directors trade stock every 92 days with the average trade being worth of $27,462. The most recent stock trade was executed by David F Hale on 9 December 2021, trading 445 units of BIOC stock currently worth $1,807.
biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar
Biocept Inc executives and other stock owners filed with the SEC include: